74 results on '"Oparil, S."'
Search Results
2. Women's health, cardiovascular risk and hypertension: the perspective still needs to improve.
3. Thirty years with LIFE-a randomized clinical trial with more than 200 published articles on clinical aspects of left ventricular hypertrophy.
4. The five RADIANCE-HTN and SPYRAL-HTN randomised studies suggest that the BP lowering effect of RDN corresponds to the effect of one antihypertensive drug.
5. Combining proteomics, home blood pressure telemonitoring and patient empowerment to improve cardiovascular and renal protection.
6. Cuff-less measurements of blood pressure: are we ready for a change?
7. Better drug adherence improves blood pressure control and lowers cardiovascular disease outcomes - from single pill combinations to monitoring of a nationwide health insurance database.
8. Blood pressure target in patients with hypertension and type-2 diabetes older than 65 years. Is <130/80 mmHg the right target or an excessive objective preventing from achieving the clinical goals we are aiming at?
9. Potential protective effects of antihypertensive treatments during the Covid-19 pandemic: from inhibitors of the renin-angiotensin system to beta-adrenergic receptor blockers.
10. Was it optimal to drop a diuretic as a first-line choice of drug treatment in the 2020 International Society of Hypertension Guidelines?
11. The International Society of Hypertension Guidelines 2020 - a new drug treatment recommendation in the wrong direction?
12. Intensive systolic blood pressure control and prevention of new onset atrial fibrillation in the SPRINT study: is the association really controversial?
13. Blood pressure medication should not be routinely dosed at bedtime. We must disregard the data from the HYGIA project.
14. How to deal with the occurrence of rare drug-induced adverse events: the example of sprue-like enteropathy induced by olmesartan medoxomil and other angiotensin-receptor blockers.
15. The Health Outcomes Prevention and Evaluation 4 (HOPE 4) project: A successful community-based intervention to lower cardiovascular risk in people with hypertension.
16. Systolic blood pressure control prevents cognitive decline and slows development of white matter lesions in the brain: the SPRINT MIND study outcomes.
17. The PARAGON-Heart failure trial - another disappointment for heart failure patients with hypertension and preserved ejection fraction.
18. The PARAGON Heart Failure trial - ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction.
19. Need for multiple risk reduction strategies in clinical trials enrolling high risk patients - FOURIER investigating PCSK-9 inhibitor to lower cholesterol revisited.
20. Will we ever use angiotensin receptor neprilysin inhibition (ARNi) for the treatment of hypertension?
21. New data on antihypertensive drugs and risk of cancer: should we worry?
22. 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension.
23. Intensive blood pressure lowering prevents mild cognitive impairment and possible dementia and slows development of white matter lesions in brain: the SPRINT Memory and Cognition IN Decreased Hypertension (SPRINT MIND) study.
24. Renal denervation achieved by endovascular delivery of ultrasound in RADIANCE-HTN SOLO or by radiofrequency energy in SPYRAL HTN-OFF and SPYRAL-ON lowers blood pressure.
25. New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden?
26. Challenges in oscillometric blood pressure measurement in atrial fibrillation: looking for practical solutions.
27. Renal denervation in hypertension: is it the end or the beginning of a SPYRAL?
28. Treatment strategies for comorbid conditions lower residual risk in patients with treated hypertension: FOURIER and other randomized outcome trials.
29. The INTERSTROKE Study: hypertension is by far the most important modifiable risk factor for stroke.
30. The INTERSALT Study and the complex relationship between salt intake and blood pressure.
31. The Global Burden of Disease Study 2015 and Blood Pressure.
32. Blood Pressure in 2016: increased impact factor and change of editors.
33. The polypill: an emerging treatment alternative for secondary prevention of cardiovascular disease.
34. The J-curve phenomenon revisited again: SPRINT outcomes favor target systolic blood pressure below 120 mmHg.
35. Renal denervation in treatment-resistant hypertension - Oslo RDN, Symplicity HTN-3 and INSPiRED randomized trials.
36. Hypertension management by practice guidelines.
37. Revisiting the pre-hypertension debate: increasing evidence for treatment--or not?
38. Blood pressure lowering effect of renal sympathetic denervation or placebo? - building expectations for Symplicity-HTN 3.
39. 2013 European Society of Hypertension/European Society of Cardiology Hypertension Guidelines.
40. Primary cardiovascular prevention by Mediterranean diet - the PREDIMED trial.
41. Angiotensin receptor--neprilysin inhibiton (ARNI)--a novel therapeutic concept for management of hypertension and heart failure.
42. Direct renin inhibitors in hypertension - approaching the moment of truth.
43. Increased time varying heart rate and cardiovascular risk in hypertension: benefit of selective I((f)) channel inhibitor?
44. An appropriate SCORE to assess cardiovascular risk in hypertension?
45. Renal nerve ablation: emerging role in therapeutics.
46. High mortality explained by mildly elevated blood pressure in Scandinavian adolescent conscripts: a plea for early drug treatment?
47. Antihypertensive therapy and cancer risks?
48. Treatment of high blood pressure in acute stroke--the SCAST study.
49. Cardiovascular risks in HIV patients.
50. Angiotensin receptor blockers and cancer - Relationship dismissed by VALUE data while waiting for EMA and FDA reports.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.